BlossomHill Therapeutics Shares Rise After Updated Trial Data for BH-30643
BlossomHill Therapeutics (NASDAQ:BLSM) shares rose 4.4% in premarket trading following the presentation of updated clinical data on its investigational drug, BH-30643, at a major lung cancer conference. The Phase 1/2 SOLARA trial showed an objective response rate of 45% and disease control rate of 88% among 40 patients with EGFR C797S-positive non-small cell lung cancer. The drug has received FDA Fast Track designation, indicating its potential to address a significant unmet medical need. The company's CEO is set to present at the H.C. Wainwright Global Investment Conference in New York. BlossomHill recently went public and currently trades above its IPO price but below its 52-week high.
Tickers: $BLSM